PAA do have a business plan which has been communicated quite a few times maybe not called a business plan, the last time it was listed was in quarterly issued 29 April 2022 and listed as activity timelines in that announcement.
The main problems have been the inability of the board to deliver to the plan / timelines and the fact that shareholders have not held the board to account.
So what did the activity timeline state
MND trial completed 21 October 2022
Start of human cancer trial December 2022
End of canine trial in 2022
Now as for the reward oppies I guess the plan may have been for the expectation that long term holders could sell the oppies, which they could have and made a 40 to 50% profit so really I guess holders took the risk in hope of a greater return so we really can not blame the company if the oppies do not get in the money
Ann: Additional Phase 1 data suggest MPL may inhibit MND, page-380
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $97.22M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.0¢ | 19.5¢ | $199.9K | 1.004M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 457971 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 1207 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |